glp-1 news nov 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Agonists Weight Loss Drugs

But heres the uplifting truth: we can test, tweak, and turn it around together

As of 2026, retatrutide holds no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation and is classed as an unlicensed investigational peptide in the UK [1][6]

And a few, particularly those related to Akkermansia muciniphila , raise legitimate safety questions that deserve serious attention, especially for people with autoimmune conditions, compromised immune systems, or inflammatory bowel disease

Proper retatrutide dosage is crucial for safe and informative research results

doi: 10.1210/endo.140.11.7143 15 MeierJJNauckMAKranzDHolstJJDeaconCFGaecklerDet al

From actors to athletes, the world cant seem to get enough of this miracle drug. This insatiable appetite has ignited a heated debate surrounding safety and ethics